Skip to content

Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations - 11

Sevoflurane vs Nitrous Oxide Inhalation at Subanesthetic Concentrations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000259
Enrollment
12
Registered
1999-09-21
Start date
1996-08-31
Completion date
1997-11-30
Last updated
2015-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid-Related Disorders, Substance-Related Disorders

Keywords

sevoflurane, nitrous oxide, subjective effects, healthy volunteer

Brief summary

The purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. Mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. Comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. To examine sevoflurane versus isoflurane inhalation at subanesthetic concentrations on mood, pain, and psychomotor performance.

Interventions

DRUG15 % Nitrous oxide
DRUG0.3 % Sevoflurane
OTHERPlacebo

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Chicago
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
21 Years to 39 Years
Healthy volunteers
Yes

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frameDescription
Pain intensity30 min of inhalationSubjects underwent a 3 min cold immersion test at 30 min of inhalation and then provided response to pain intensity questionnaire
Psychomotor performanceBaseline, 5 min of inhalation; 5, 30, 60 minutes recoverySubjects underwent psychomotor testing at baseline, during inhalation, and during recovery post inhalation
Cognitive performanceBaseline, every 5 min during inhalation, 5, 30, & 60 min during recoverySubject underwent memory, sedation, visual analog, and drug effects testing

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026